REFERENCES
- Bellamy W T, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427–1434, [PUBMED], [INFOTRIEVE], [CSA]
- Brynes R K, Swayne D, McCourty A, Dosik G M, Traweek S T, Slovak M L. Detection of trisomy 8 by fluorescence in situ hybridization on bone marrow smears from patients with subtle myelodysplastic changes. Arch Pathol Lab Med 1994; 118: 1196–1200, [PUBMED], [INFOTRIEVE], [CSA]
- Hasle H, Clausen N, Pedersen B. Bendix-Hansen K. Myelodysplastic syndrome in a child with constitutional trisomy 8 mosaicism and normal phenotype. Cancer Genet Cytogenet 1995; 79: 79–81, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Narendran A, Ganjavi H, Morson N, et al. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp Hematol 2003; 31: 693–701, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Narendran A, Hawkins L M, Ganjavi H, et al. Characterization of bone marrow stromal abnormalities in a patient with constitutional trisomy 8 mosaicism and myelodysplastic syndrome. Pediatr Hematol Oncol 2004; 21: 209–221, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brunner B, Gunsilius E, Schumacher P, Zwierzina H, Gastl G, Stauder R. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res 2002; 11: 119–125, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Albitar M. Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol 2001; 106: 170–176, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Workman P. Overview: translating Hsp90 biology into Hsp90 drugs. Curr Cancer Drug Targets 2003; 3: 297–300, [PUBMED], [INFOTRIEVE], [CSA]
- Chavany C, Mimnaugh E, Miller P, et al. p185erbB2 binds to GRP94 in vivo: dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem 1996; 271: 4974–4977, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Whitesell L, Cook P. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol Endocrinol 1996; 10: 705–712, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nguyen D M, Desai S, Chen A, Weiser T S, Schrump D S. Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin. Ann Thorac Surg 2000; 70: 1853–1860, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mabjeesh N J, Post D E, Willard M T, et al. Geldanamycin induces degradation of hypoxia-inducible factor lalpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002; 62: 2478–2482, [PUBMED], [INFOTRIEVE]
- Poulaki V, Mitsiades C S, McMullan C, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab 2003; 88: 5392–5398, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hostein I, Robertson D, DiStefano F, Workman P, Clarke P A. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001; 61: 4003–4009, [PUBMED], [INFOTRIEVE]
- Kamel-Reid S, Dick J E, Greaves A, et al. Differential kinetics of engraftment and induction of CD10 on human pre-B leukemia cell lines in immune deficient scid mice. Leukemia 1992; 6: 8–17, [PUBMED], [INFOTRIEVE]
- Kumagai M, Manabe A, Pui C H, et al. Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest 1996; 97: 755–760, [PUBMED], [INFOTRIEVE], [CSA]
- List A F, Garewal H S, Sandberg A A. The myelodysplastic syndromes: biology and implications for management. J Clin Oncol 1990; 8: 1424–1441, [PUBMED], [INFOTRIEVE]
- List A F. New approaches to the treatment of myelodysplasia. Oncologist 2002; 7(Suppl 1)39–49, [PUBMED], [INFOTRIEVE]
- Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92: 4150–4166, [PUBMED], [INFOTRIEVE], [CSA]
- Aguayo A. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes. Curr Hematol Rep 2004; 3: 184–191, [PUBMED], [INFOTRIEVE], [CSA]
- Wax S, Piecyk M, Maritim B, Anderson P. Geldanamycin inhibits the production of inflammatory cytokines in activated macrophages by reducing the stability and translation of cytokine transcripts. Arthritis Rheum 2003; 48: 541–550, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Richter K, Buchner J. Hsp90: chaperoning signal transduction. J Cell Physiol 2001; 188: 281–290, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Blagosklonny M V. STI-571 must select for drug-resistant cells but ‘ no cell breathes fire out of its nostrils like a dragon. ’. Leukemia 2002; 16: 570–572, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci USA 2002; 99: 12847–12852, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- An W G, Schulte T W, Neckers L M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 2000; 11: 355–360, [PUBMED], [INFOTRIEVE], [CSA]
- Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 407–410, [PUBMED], [INFOTRIEVE], [CROSSREF]
- George P, Bali P, Cohen P, et al. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 2004; 64: 3645–3652, [PUBMED], [INFOTRIEVE]
- Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, Grant S. Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 2003; 63: 8420–8427, [PUBMED], [INFOTRIEVE]
- Yao Q, Nishiuchi R, Li Q, Kumar A R, Hudson W A, Kersey J H. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res 2003; 9: 4483–4493, [PUBMED], [INFOTRIEVE], [CSA]
- Gorre M E, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers C L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002; 100: 3041–3044, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nimmanapalli R, O’Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001; 61: 1799–1804, [PUBMED], [INFOTRIEVE]